Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression - PubMed
- ️Sun Jan 01 2006
Review
. 2006 Oct 30;25(51):6817-30.
doi: 10.1038/sj.onc.1209942.
Affiliations
- PMID: 17072330
- DOI: 10.1038/sj.onc.1209942
Review
Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression
D S Bassères et al. Oncogene. 2006.
Abstract
Abundant data support a key role for the transcription factor nuclear factor-kappaB (NF-kappaB) signaling pathway in controlling the initiation and progression of human cancer. NF-kappaB and associated regulatory proteins such as IkappaB kinase (IKK) are activated downstream of many oncoproteins and there is much evidence for the activation of NF-kappaB-dependent target genes in a variety of solid tumors and hematologic malignancies. This review focuses on the mechanisms by which the NF-kappaB pathway is activated in cancer and on the oncogenic functions controlled by activated NF-kappaB. Additionally, the effects of NF-kappaB activation in tumors relative to cancer therapy are also discussed.
Similar articles
-
NF-kappaB and IKK as therapeutic targets in cancer.
Kim HJ, Hawke N, Baldwin AS. Kim HJ, et al. Cell Death Differ. 2006 May;13(5):738-47. doi: 10.1038/sj.cdd.4401877. Cell Death Differ. 2006. PMID: 16485028 Review.
-
NF-kappaB in cancer--a friend turned foe.
Ravi R, Bedi A. Ravi R, et al. Drug Resist Updat. 2004 Feb;7(1):53-67. doi: 10.1016/j.drup.2004.01.003. Drug Resist Updat. 2004. PMID: 15072771 Review.
-
The NF-kappaB/IkappaB signaling system: a molecular target in breast cancer therapy.
Wu JT, Kral JG. Wu JT, et al. J Surg Res. 2005 Jan;123(1):158-69. doi: 10.1016/j.jss.2004.06.006. J Surg Res. 2005. PMID: 15652965 Review.
-
Tsai J, Zhang R, Qiu W, Su Q, Naples M, Adeli K. Tsai J, et al. Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1287-98. doi: 10.1152/ajpgi.90540.2008. Epub 2009 Apr 2. Am J Physiol Gastrointest Liver Physiol. 2009. PMID: 19342510
-
Hanson JL, Hawke NA, Kashatus D, Baldwin AS. Hanson JL, et al. Cancer Res. 2004 Oct 15;64(20):7248-55. doi: 10.1158/0008-5472.CAN-03-3898. Cancer Res. 2004. PMID: 15492243
Cited by
-
Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model.
Yin T, He S, Shen G, Ye T, Guo F, Wang Y. Yin T, et al. Mol Med Rep. 2015 Sep;12(3):4103-4108. doi: 10.3892/mmr.2015.3967. Epub 2015 Jun 22. Mol Med Rep. 2015. PMID: 26095429 Free PMC article.
-
Sources of dynamic variability in NF-κB signal transduction: a mechanistic model.
Mothes J, Busse D, Kofahl B, Wolf J. Mothes J, et al. Bioessays. 2015 Apr;37(4):452-62. doi: 10.1002/bies.201400113. Epub 2015 Jan 30. Bioessays. 2015. PMID: 25640005 Free PMC article.
-
Ray S, Saha D, Alam N, Mitra Mustafi S, Mandal S, Sarkar A, Majumder B, Murmu N. Ray S, et al. Int J Exp Pathol. 2021 Apr;102(2):80-92. doi: 10.1111/iep.12386. Epub 2021 Mar 3. Int J Exp Pathol. 2021. PMID: 33655604 Free PMC article.
-
Tyan YS, Lee YP, Chuang HY, Wang WH, Hwang JJ. Tyan YS, et al. Biosci Rep. 2021 May 28;41(5):BSR20204203. doi: 10.1042/BSR20204203. Biosci Rep. 2021. PMID: 33974005 Free PMC article.
-
Morel KL, Hamid AA, Clohessy JG, Pandell N, Ellis L, Sweeney CJ. Morel KL, et al. Mol Cancer Res. 2021 Jul;19(7):1137-1145. doi: 10.1158/1541-7786.MCR-21-0099. Epub 2021 Apr 16. Mol Cancer Res. 2021. PMID: 33863813 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources